Table 1 Clinical and genomic characteristics of the cell lines used for high-throughput drug screening.
From: High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
Cell Line | Age at Diagnosis | Pathology at collection | Sample Origin | Treatment status at collection | BRAF/KRAS/NRAS mutation status | Seeding density (cells/well) |
|---|---|---|---|---|---|---|
iOvCa241 | 51 | Advanced LGSOC | Ascites | Post chemotherapy | KRAS (G12D) | 1800 |
VOA-14202 | 73 | Recurrent LGSOC | Tumor | Post anti-hormone | KRAS (G12V) | 1500 |
VOA-7681 | 59 | Advanced LGSOC | Tumor | Treatment naïve | KRAS (G12V) | 1700 |
VOA-1056 | 61 | Advanced MPSBT with invasive implants/IIIC | Tumor | Treatment Naïve | NRAS (Q61R) | 800 |
VOA-6406 | 56 | Recurrent LGSOC | Tumor | Post chemotherapy | NRAS (Q61R) | 1900 |
VOA-10841 | 72 | Advanced LGSOC | Tumor | Treatment Naïve | NRAS (Q61K) | 1050 |
VOA-3448 | 42 | Recurrent LGSOC with MP/IC | Ascites | Post chemotherapy and anti-hormone therapy | Wildtype | 1000 |
VOA-3723a | 42 | Recurrent LGSOC with MP/IC | Ascites | Post chemotherapy and anti-hormone therapy | Wildtype | 1900 |
VOA-4627 | 41 | Recurrent LGSOC | Ascites | Post chemotherapy (Carboplatin/Taxol, Gemcitabine), Letrozole, Avastin, and PARP inhibitor | Wildtype | 600 |
VOA-4698b | 41 | Recurrent LGSOC | Ascites | Post chemotherapy (Carboplatin/Taxol, Gemcitabine), Letrozole, Avastin, and PARP inhibitor | Wildtype | 450 |
AOCS-2 | 28 | Recurrent LGSOC | Ascites | Post chemotherapy | Wildtype | 750 |
SLC58 | 67 | Recurrent LGSOC | Ascites | Post chemotherapy | Wildtype | 1050 |
IOSE-523 | Unknown | Ovary, surface epithelium | Wildtype | 350 |
